Overall survival for oncology drugs approved for genomic indications-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overall survival for oncology drugs approved for genomic indications

Published:2022-01 Issue: Volume:160 Page:175-179
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Haslam Alyson^ORCID,Kim Myung Sun^ORCID,Prasad Vinay

Funder

Arnold Ventures

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Strength of validation for surrogate end points used in the US food and drug administration's approval of oncology drugs;Kim;Mayo Clin Proc,2016

2. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US food and drug administration approvals;Kim;JAMA Intern Med,2015

3. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020;Haslam;Ann Oncol,2021

4. Surrogate end points and patient-reported outcomes for novel oncology drugs approved between 2011 and 2017;Zettler;JAMA Oncol,2019

5. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines;Salas-Vega;JAMA Oncol,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

2. The Most Disruptive Near-Term Use of AI in Cancer Care: Patient Empowerment Through Software Agents;AI in Precision Oncology;2024-08-30

3. Competition, value-based prices and incentives to research personalised drugs;Socio-Economic Planning Sciences;2024-06

4. Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients;Journal of Laboratory Medicine;2024-04-19

5. Timely, Cheap, or Risk-Free? The Effect of Regulation on the Price and Availability of New Drugs;Pharmacy;2024-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3